All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): NILK-2301
Therapeutic Area: Oncology Product Name: NILK-2301
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: LamKap Bio Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2020
Details:
Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Lenzilumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Kodiak Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 27, 2020
Details:
Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Abelacimab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Anthos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2020
Details:
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Wnt Activating Antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Surrozen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 01, 2020
Details:
Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Xortx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020
Details:
Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): TAC01-HER2
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Triumvira Immunologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 24, 2020
Details:
Collaboration, aimed at developing Triumvira’s TAC01-HER2 T-cell therapy for solid tumors, will leverage Lonza’s expertise in process development and the usage of its proprietary Cocoon® Platform.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): RP-L201
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Recipient: Rocket Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Partnership January 30, 2020
Details:
The agreement covers development and manufacturing of RP-L201, a phase 1/2 candidate for the treatment of Leukocyte Adhesion Deficiency-I (LAD-I).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
